Vistagen (VTGN) news
Recent news
SRX Global buys stake in Vistagen Therapeutics
AInvest Wire · Aug 4, 2026Vistagen Therapeutics - plans to meet with FDA on registration pathway for Fasdiyenol with future Phase 3 trial
AInvest Wire · Jun 30, 2026Vistagen Therapeutics Inc: Fasdienol did not achieve statistically significant improvement on primary and secondary endpoints
Vistagen Therapeutics Inc. (Nasdaq: VTGN) announced that its Phase 3 clinical trial, PALISADE-3, of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate statistically significant improvement on the primary endpoint of anxiety reduction as measured by the…
AInvest Wire · Jun 30, 2026Vistagen Therapeutics - topline results from Palisade-4 Phase 3 trial expected in Q2 2026
AInvest Wire · Jun 9, 2026Rosen Law Firm Reminds Vistagen Therapeutics Investors of March 16 Lead Plaintiff Deadline
Rosen Law Firm is reminding investors who purchased Vistagen Therapeutics common stock between April 1, 2024 and December 16, 2025 of the March 16, 2026 lead plaintiff deadline. Investors may be entitled to compensation without paying fees or costs through a contingency fee arrangement. To join the…
AInvest Wire · Mar 5, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.